The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels of Stromal-Derived Factor-1 Alpha

Experimental and Clinical Endocrinology and Diabetes

Volumn 126, Issue 6, 2018, Pages 367-370

  Papazafiropoulou, Athanasia K ^a   Papanas, Nikolaos ^b   Trikkalinou, Aikaterini ^a   Fousteris, Evaggelos ^a   Melidonis, Andreas ^a  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

DPP 4 inhibitiors; sitagliptin; stromal derived factor 1 ; treatment; type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; CXCL12 PROTEIN, HUMAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; STROMAL CELL DERIVED FACTOR 1;

AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UPREGULATION;

ADMINISTRATION, ORAL; AGED; CHEMOKINE CXCL12; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; UP-REGULATION;

EID: 85029721534     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0043-118748     Document Type: Article

References (30)

1. Drucker D. J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care: 2007; 30 1335 1343
2. Aroor A. R. Sowers J. R. Jia G. et al. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol: 2014; 307 H477 H492
3. Kim H. S. Shin J. A. Lee S. H. et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther: 2013; 15 810 816
4. Derosa G. Bonaventura A. Bianchi L. et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism: 2014; 63 957 967
5. Koren S. Shemesh-Bar L. Tirosh A. et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther: 2012; 14 561 567
6. Scirica B. M. Bhatt D. L. Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med: 2013; 369 1317 1326
7. White W. B. Cannon C. P. Heller S. R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med: 2013; 369 1327 1335
8. Green J. B. Bethel M. A. Armstrong P. W. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med: 2015; 373 232 242
9. Fadini G. P. Boscaro E. Albiero M. et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha. Diabetes Care: 2010; 33 1607 1609
10. Proost P. Struyf S. Schols D. et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett: 1998; 432 73 76
11. Yano T. Liu Z. Donovan J. et al. Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. Diabetes: 2007; 56 2946 2957
12. Stokman G. Stroo I. Claessen N. et al. SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant: 2010; 5 3852 3859
13. Fadini G. P. Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis: 2013; 229 23 29
14. Subramanian S. Liu C. Aviv A. et al. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol: 2014; 34 2100 2105
15. Huang C. Y. Shih C. M. Tsao N. W. et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol: 2012; 167 1506 1519
16. Shih C. M. Chen Y. H. Lin Y. W. et al. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Curr Med Chem: 2014; 21 2012 2022
17. Fadini G. P. Bonora B. M. Cappellari R. et al. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab: 2016; 101 748 756
18. Yorifuji N. Inoue T. Iguchi M. et al. The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice. Oncol Rep: 2016; 35 676 682
19. Fujita H. Taniai H. Murayama H. et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr J: 2014; 61 159 166
20. Dei Cas A. Spigoni V. Cito M. et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: A 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol: 2017; 16 27
21. Park K. S. Kwak S. Cho Y. M. et al. Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig: 2017; 8 218 826
22. Aso Y. Jojima T. Iijima T. et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34(+)CXCR4(+) cells in patients with type 2 diabetes. Endocrine: 2015; 50 659 664
23. Hristov M. Zernecke A. Bidzhekov K. et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res: 2007; 100 590 597
24. Li M. Yu J. Li Y. et al. CXCR4 positive bone mesenchymal stem cells migrate to human endothelial cell stimulated by ox-LDL via SDF-1alpha/CXCR4 signaling axis. Exp Mol Pathol: 2010; 88 250 255
25. Abi-Younes S. Sauty A. Mach F. et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res: 2000; 86 131 138
26. Brenner C. Franz W. M. Köhlenthal S. et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. Int J Cardiol: 2015; 199 163 169
27. Mehta N. N. Matthews G. J. Krishnamoorthy P. et al. Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: Findings from the Chronic Renal Insufficiency Cohort study. Eur Heart J: 2014; 35 2115 2122
28. Papanas N. Maltezos E. Antidiabetic treatment: Though lovers be lost, love shall not. World J Diabetes: 2012; 3 158 160
29. Dhamodharan U. Viswanathan V. Krishnamoorthy E. et al. Genetic association of IL-6, TNF-α and SDF-1 polymorphisms with serum cytokine levels in diabetic foot ulcer. Gene: 2015; 565 62 67
30. Kočí Z. Turnovcová K. Dubský M. et al. Characterization of human adipose tissue-derived stromal cells isolated from diabetic patient's distal limbs with critical ischemia. Cell Biochem Funct: 2014; 32 597 604